Abstract | BACKGROUND: METHODS: The rate of death, myocardial infarction, and urgent revascularization at days 8 and 43 after randomization was compared among patients who received aspirin within the week before randomization with those who did not receive aspirin in the TIMI 11B trial. A total of 3275 patients (84%) were prior aspirin users. RESULTS: The admission diagnosis was similar for prior and nonprior aspirin users. At both day 8 and day 43 the event rate was higher for prior aspirin users than for nonprior aspirin users (odds ratio 1.6 [1.24-2.08], P =.0004 at day 43), even after correction for baseline characteristics. Compared with those prior aspirin users taking UFH, enoxaparin-treated prior aspirin users had a reduced rate of the composite end point of death, myocardial infarction, and urgent revascularization at day 8 (odds ratio 0.82 [0.67-1.00], P =.046) and day 43 (odds ratio 0.83 [0.70-0.98], P =.032). CONCLUSION: Patients with UA/ NSTEMI and prior aspirin use had a 60% higher risk of death and cardiac ischemic events compared with nonprior aspirin users. On the basis of this subanalysis, enoxaparin is superior to UFH in all patients. In prior aspirin users the benefit is more clearly demonstrated.
|
Authors | J Santopinto, E P Gurfinkel, V Torres, E Marcos, G E Bozovich, B Mautner, C H McCabe, E M Antman |
Journal | American heart journal
(Am Heart J)
Vol. 141
Issue 4
Pg. 566-72
(Apr 2001)
ISSN: 0002-8703 [Print] United States |
PMID | 11275921
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anticoagulants
- Enoxaparin
- Platelet Aggregation Inhibitors
- Heparin
- Aspirin
|
Topics |
- Angina, Unstable
(drug therapy)
- Anticoagulants
(therapeutic use)
- Aspirin
(therapeutic use)
- Double-Blind Method
- Enoxaparin
(therapeutic use)
- Female
- Heparin
(therapeutic use)
- Humans
- Logistic Models
- Male
- Middle Aged
- Myocardial Infarction
(drug therapy)
- Platelet Aggregation Inhibitors
(therapeutic use)
- Prognosis
- Risk Assessment
- Syndrome
|